Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection

International Journal of Drug Policy

Volumn 47, Issue , 2017, Pages 239-243

  Artenie, Andreea Adelina ^a,b   Zang, Geng ^b   Daniel, Mark ^c,d   Fortier, Emmanuel ^a,b   Jutras Aswad, Didier ^a,b   Puzhko, Svetlana ^e   Bruneau, Julie ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

Antiviral treatment; Cohort study; HCV; Hepatitis C care; Injection drug use; People who inject drugs

Indexed keywords

PEGINTERFERON ALPHA;

ADULT; AGE; ARTICLE; CANADA; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG CONTRAINDICATION; DRUG USE; FEMALE; FOLLOW UP; GENDER; HEALTH SERVICE; HEPATITIS C; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NAMED GROUPS OF PERSONS; PEOPLE WHO INJECT DRUG; PRIORITY JOURNAL; PROSPECTIVE STUDY; ADDICTION; COMPLICATION; HIGH RISK BEHAVIOR; PSYCHOLOGY; SUBSTANCE ABUSE; YOUNG ADULT;

ADULT; BEHAVIOR, ADDICTIVE; FEMALE; HEPATITIS C; HUMANS; LONGITUDINAL STUDIES; MALE; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 85020095979     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2017.05.033     Document Type: Article

References (17)

1. Alavi, M., Spelman, T., Matthews, G.V., Haber, P.S., Day, C., van Beek, I., et al. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian trial in acute hepatitis C. International Journal of Drug Policy 26:10 (2015), 976–983.
2. Aspinall, E.J., Weir, A., Sacks-Davis, R., Spelman, T., Grebely, J., Higgs, P., et al. Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the networks II study. International Journal of Drug Policy 25:1 (2014), 179–182.
3. Bruneau, J., Brogly, S.B., Tyndall, M.W., Lamothe, F., Franco, E.L., Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: The interface with social factors and service utilization. Addiction 99:6 (2004), 727–737.
4. Bruneau, J., Zang, G., Abrahamowicz, M., Jutras-Aswad, D., Daniel, M., Roy, E., Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: A longitudinal study. Clinical Infectious Diseases 58:6 (2014), 755–761.
5. Dore, G.J., Altice, F., Litwin, A.H., Dalgard, O., Gane, E.J., Shibolet, O., et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: A randomized trial. Annals of Internal Medicine 165:9 (2016), 625–634.
6. Friedmann, P.D., Zhang, Z., Hendrickson, J., Stein, M.D., Gerstein, D.R., Effect of primary medical care on addiction and medical severity in substance abuse treatment programs. Journal of General Internal Medicine 18:1 (2003), 1–8.
7. Grebely, J., Bruggmann, P., Treloar, C., Byrne, J., Rhodes, T., Dore, G.J., Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy 26:10 (2015), 893–898.
8. Higgs, P., Wright, C., Hellard, M., Letter: new treatments for hepatitis C have implications for quality of life in people who inject drugs. Alimentary Pharmacology & Therapeutics 43:7 (2016), 840–841.
9. Ly, K.N., Hughes, E.M., Jiles, R.B., Holmberg, S.D., Rising mortality associated with hepatitis C virus in the United States, 2003–2013. Clinical Infectious Diseases 62:10 (2016), 1287–1288.
10. Nambiar, D., Agius, P.A., Stoove, M., Hickman, M., Dietze, P., Cessation of injecting drug use: The effects of health service utilisation, drug use and demographic factors. Drug and Alcohol Dependence 154 (2015), 208–213.
11. Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 378:9791 (2011), 571–583.
12. Rothman, K.J., Greenland, S., Lash, T.L., Modern epidemiology. 2008, Lippincott Williams and Wilkins, Philadelphia, PA.
13. Saitz, R., Horton, N.J., Larson, M.J., Winter, M., Samet, J.H., Primary medical care and reductions in addiction severity: A prospective cohort study. Addiction 100:1 (2005), 70–78.
14. Scott, N., McBryde, E.S., Thompson, A., Doyle, J.S., Hellard, M.E., Treatment scale-up to achieve global HCV incidence and mortality elimination targets: A cost-effectiveness model. Gut, 2016, 10.1136/gutjnl-2016-311504.
15. Spelman, T., Morris, M.D., Zang, G., Rice, T., Page, K., Maher, L., et al. A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs. Journal of Epidemiology and Community Health 69:8 (2015), 745–752.
16. World Health Organization, Guidelines for the screening, care and treatment of persons with hepatitis C infection. 2014, World Health Organization, Geneva.
17. Younossi, Z.M., Stepanova, M., Nader, F., Lam, B., Hunt, S., The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: A study of health-related quality of life. Alimentary Pharmacology & Therapeutics 42:3 (2015), 286–295.